bluebird bio (LTS:0HOH) Debt-to-Asset : 0.79 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is bluebird bio Debt-to-Asset?

bluebird bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $194.67 Mil. bluebird bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $173.73 Mil. bluebird bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $465.06 Mil. bluebird bio's debt to asset for the quarter that ended in Sep. 2024 was 0.79.

bluebird bio Debt-to-Asset Historical Data

The historical data trend for bluebird bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Debt-to-Asset Chart

bluebird bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.11

0.04

0.15

0.64

0.53

bluebird bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.50	0.53	0.66	0.72	0.79

Competitive Comparison of bluebird bio's Debt-to-Asset

For the Biotechnology subindustry, bluebird bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bluebird bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where bluebird bio's Debt-to-Asset falls into.

bluebird bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

bluebird bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(105.907	+	224.419)	/	619.161
	=	0.53

bluebird bio's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(194.671	+	173.731)	/	465.056
	=	0.79

bluebird bio (LTS:0HOH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

bluebird bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of bluebird bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (LTS:0HOH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BLUE:USA BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

bluebird bio Headlines

No Headlines